XML 60 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statement of Changes in Equity - USD ($)
$ in Millions
Total
Share capital
Other reserves
Fair value adjustments on equity investments
Actuarial (losses)/gains from defined benefit plans
Cumulative currency translation effects
Total value adjustments
 [1]
Beginning balance at Dec. 31, 2020 $ 18,822 $ 20 $ 18,899 $ (32) $ (109) $ 44 $ (97)
Changes in equity [abstract]              
Net income 376   376        
Other comprehensive income/(loss) (32)       26 (58) (32)
Total comprehensive income 344   376 0 26 (58) (32)
Dividends (53)   (53)        
Equity-based compensation 124   124        
Other movements [2] 19   10   9   9
Total other movements 90   81   9   9
Ending balance at Dec. 31, 2021 19,256 20 19,356 (32) (74) (14) (120)
Changes in equity [abstract]              
Net income 335   335        
Other comprehensive income/(loss) 104     (1) 141 (36) 104
Total comprehensive income 439   335 (1) 141 (36) 104
Dividends (102)   (102)        
Equity-based compensation 68   68        
Other movements [2] 16   16        
Total other movements (18)   (18)        
Ending balance at Dec. 31, 2022 19,677 20 19,673 (33) 67 (50) (16)
Changes in equity [abstract]              
Net income 974   974        
Other comprehensive income/(loss) (10)     (5) (30) 25 (10)
Total comprehensive income 964   974 (5) (30) 25 (10)
Dividends (117)   (117)        
Equity-based compensation 86   86        
Other movements [2] 14   8 6     6
Total other movements (17)   (23) 6     6
Ending balance at Dec. 31, 2023 $ 20,624 $ 20 $ 20,624 $ (32) $ 37 $ (25) $ (20)
[1] "Total value adjustments" are presented net of the corresponding tax effects.
[2]     Activity includes hyperinflationary accounting (see Note 2). The year ended December 31, 2023 also includes a reclassification to Other reserves related to the sale of an equity investment. The year ended December 31, 2021 primarily includes an adjustment to actuarial gains to recognize plan assets related to the separation of a pension plan in the spin-off from Novartis but which were not previously recorded.